Experimental brain tumor combo shows promise in early trial
NCT ID NCT02942264
First seen Feb 23, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tested an experimental drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find safe doses and see if the combination works better than temozolomide alone. The trial was terminated early, but it provided safety and dosing information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.